Background: The objective of this study was to evaluate the usefulness of American Thyroid Association (ATA) risk classification and dynamic risk stratification (DRS) based on the response to initial therapy in pediatric patients with differentiated thyroid cancer (DTC).
D
ifferentiated thyroid cancer (DTC) is one of the most common cancers in young female patients, and the incidence has been increasing for the last few decades (1, 2) . In the United States, 1.8% of new thyroid cancers were found in patients younger than 20 years according to Surveillance, Epidemiology and End Results data (3) . Papillary thyroid cancer is the most common thyroid cancer, and follicular thyroid cancer is relatively uncommon in pediatric thyroid cancer (4) (5) (6) (7) . The clinical behavior of DTC in pediatric patients was known to be different from that in adult patients. Compared with adults, pediatric patients with DTC tend to have more cervical lymph node (LN) metastases, extrathyroidal extension, and lung metastasis (4, (8) (9) (10) (11) . However, the mortality of pediatric patients was lower despite more extensive disease and recurrent/persistent disease (9, (12) (13) (14) (15) .
Currently no single postoperative staging system has been validated in pediatric patients with DTC (16) . The American Joint Committee on Cancer Tumor Node Metastasis (TNM) staging system is commonly used in clinical practice. However, TNM staging has limited value for the pediatric patient because all patients younger than 45 years were classified as having stage I (without distant metastasis) or II disease (with distant metastasis). Recent guidelines of American Thyroid Association (ATA) categorized pediatric patients into 3 risk groups to identify the risk of persistent cervical disease and to determine postoperative work-up and follow-up strategy (16) . In this classification, the low-risk group was defined as having intrathyroidal disease or incidental N1a disease (microscopic metastasis to a small number of central neck LNs), and the intermediate risk group was defined as having extensive N1a or minimal N1b disease. However, exact cutoff points to classify each risk group were not presented, and there were limited data to support the clinical usefulness of this risk classification in pediatric patients with DTC (17, 18) .
Recently, the importance of dynamic risk stratification (DRS) based on the response to initial therapy for individualization of the management recommendations was emphasized in patients with DTC (19) . This approach could provide surveillance and therapeutic strategies during the follow up according to levels of serum thyroglobulin (Tg) and anti-Tg antibody (TgAb) and results of diagnostic imaging during follow up as a marker of the response to therapy. However, this ongoing risk stratification has been validated only in adult patients with DTC, and there has been no study about DRS in pediatric patients.
In this study, we evaluated the usefulness of initial ATA risk classification using extent of disease, including the size and number of metastatic cervical LNs in pediatric patients with DTC. We also evaluated the importance of DRS based on the response to the initial therapy compared with the initial ATA risk classification.
Materials and Methods

Study subjects
This retrospective cohort study initially included 88 pediatric patients who underwent initial thyroid surgery and were diagnosed with DTC between January 1995 and December 2014 at Asan Medical Center in Seoul, Korea. Pathologic specimens were reviewed by an experienced endocrine pathologist (D.E.S). We excluded 11 patients who did not have adequate follow-up information. A total of 77 pediatric patients were eligible for this study. Sixty-four patients (82%) underwent total thyroidectomy and subsequent radioactive iodine (RAI) remnant ablation. Thirteen patients underwent thyroid lobectomy. This study was approved by the institutional review board of Asan Medical Center.
Risk stratification of DTC
To assess the initial anatomical risk stratification, patients were categorized according to the American Joint Committee on Cancer TNM staging system (20) . Patients were stratified into 3 groups according to the risk level at initial therapy based on the newly proposed ATA pediatric risk stratification system: low, intermediate, or high risk (16 (19, 22, 23) .
We also classified patients according to the best response to the initial therapy with respect to the modified DRS of DTC as previously reported: excellent response, indeterminate response, biochemical incomplete response, or structural incomplete response (24) (25) (26) . We evaluated the best response after initial therapy during the first 2 years of follow up by using the level of serum Tg and TgAb and results of imaging studies (Table 2 ). In patients who underwent total thyroidectomy with RAI remnant ablation and measured stimulated Tg (sTg) level during follow up, excellent response was defined as serum sTg ,1 ng/mL with negative TgAb and without any suspicious findings in images. Indeterminate response was defined as low serum sTg level (1 to 10 ng/mL) or stable positive serum TgAb with negative findings in images. Biochemical incomplete response was defined as serum sTg .10 ng/mL or rising serum TgAb without any suspicious findings in images (24) . In patients who underwent total thyroidectomy with RAI remnant ablation without measurement of sTg level during follow up, suppressed Tg and TgAb levels were used to determine the best response to initial therapy as patients who underwent total thyroidectomy without RAI ablation (26) . Excellent response was defined as serumsuppressed Tg ,0.2 ng/mL with negative TgAb and negative imaging findings. Indeterminate response was defined as detectable but low serum-suppressed Tg level (0.2 to 1.0 ng/mL) or stable positive serum TgAb without any suspicious findings in images. Biochemical incomplete response was defined as serum Tg level .1 ng/mL or as rising serum TgAb with negative imaging findings. In a patient who underwent lobectomy, 
Management and follow up
The management protocol was shared at our center to maintain consistent treatment and follow up across the patients. All patients were administered levothyroxine and were regularly followed with physical examination, thyroid function test, neck ultrasonography, and measurement of serum Tg and TgAb levels at 6-to 12-month intervals. Diagnostic RAI whole body scan was done at the first 9 to 18 month after initial therapy in patients who underwent total thyroidectomy. If structural lesions needed further evaluations, additional diagnostic imaging studies, including neck/chest computed tomography and wholebody fluoro-deoxyglucose positron emission tomography/ computed tomography, were performed in addition to pathological or cytological tests to confirm local recurrence or distant metastasis.
Definitions of clinical outcomes
Patients with negative serum Tg, negative TgAb, and no suspicious structural disease at the end of the follow up were considered to have no clinical evidence of disease (NED). In patients who underwent total thyroidectomy with RAI ablation, biochemical persistent disease was defined as stimulated or suppressed Tg level .1 ng/mL or as positive TgAb with negative imaging findings at the end of follow up. In patients who underwent lobectomy, biochemical persistent disease was defined as serum Tg level .30 ng/mL without evidence of structural disease. Structural persistent/recurrent disease was defined as pathologically or cytologically proven metastatic lesions or metastatic lesions in distant organs by imaging studies with detectable Tg levels at the end of follow up. DFS was defined as the time interval between the initial surgery and the detection of structural persistent/recurrent disease (22, 23) .
Statistical analysis
All statistical analyses were conducted using R (version 3.1.0) and the R library package (R Foundation for Statistical Computing, Vienna, Austria). Continuous variables are presented as the medians with interquartile range (IQR). Categorical variables are presented as numbers with percentages. Fisher's exact test was used to evaluate the association of initial and dynamic risk stratification with clinical outcomes. DFS curves were constructed using the Kaplan-Meier method, and log-rank test was used to evaluate differences in DFS between groups. Cox proportional hazard model was used to evaluate the risk of structural recurrence/persistence of disease. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated. A P value ,0.05 was considered statistically significant. All P values were 2-sided.
Results
Baseline characteristics of pediatric patients with DTC
The baseline clinical and pathological characteristics of the 77 pediatric patients with DTC are listed in Table 3 . The median age of study subjects was 16 years (IQR, 14 to 17), and 57 (74%) were female. Six patients (7%) were under 10 years old, and 28 patients (36%) were between 10 and 15 years old. Fifty-six patients (73%) had palpable masses as an initial presentation. Classic papillary Structural recurrent/persistent disease was detected in 18 patients (23%), including 14 (18%) with locoregional disease and 4 (5%) with distant metastasis during a median 5.3 years (IQR, 2.7 to 10.0) of follow up. When we analyzed the risk of structural recurrent/ persistent disease according to various clinicopathological characteristics, large primary tumor (.4 cm), gross extrathyroidal extension, and lateral cervical LN metastasis were independent risk factors (Supplemental Table 1 ).
Clinical outcomes according to the ATA pediatric risk classification
Based on the ATA pediatric risk classification, 17 patients (22%) were in the low-risk group, 37 patients (48%) were in the intermediate-risk group, and 23 patients (30%) were in the high-risk group. The clinical outcomes at the end of the follow up were significantly associated with the initial ATA pediatric risk classification (P , 0.001). Most of the patients (95%) in the low-risk group had NED at the end of follow up. Among 23 patients in the high-risk group, 5 patients (22%) had NED, but 17 patients (74%) had structural persistent/recurrent disease at the end of follow up (Table 4 ). There was a significant difference in DFS according to the ATA pediatric risk classification in our study subjects (P , 0.001) [ Fig. 1(A) ]. Five-year DFS rates were 94% in the low-risk group, 73% in the intermediaterisk group, and 28% in the high-risk group. The risk of recurrent/persistent disease was significantly higher only in the high-risk group (HR, 18.35; 95% CI, 2.44 to 138.21; P = 0.005) ( Table 5 ). There was no significant difference in DFS between the intermediate-risk and lowrisk groups.
Clinical outcomes according to the DRS based on the best response to the initial therapy
The numbers of patients in the 4 groups according to the DRS were as follows: 38 patients (49%) in the excellent response group, 10 patients (13%) in the indeterminate response group, 5 patients (6%) in the biochemical incomplete response group, and 24 patients (31%) in the structural incomplete response group. All patients who underwent lobectomy had excellent response. The clinical outcomes at the end of the follow up according to the DRS are shown in Table 4 and demonstrate a significant association (P , 0.001). Patients with excellent response had the highest likelihood of being NED (97%). Only 4% of patients with structural incomplete response became NED state, and 88% of them had confirmed structural persistent/ recurrent disease (Table 4) . Nine patients did not have excellent response by DRS but finally had NED. Six patients with indeterminate response, and 2 patients with biochemical incomplete response spontaneously developed NED without additional treatment. One patient with structural incomplete response had suspicious lymph node enlargement at first evaluation, but it turned out to be reactive change by fine-needle aspiration cytology. There was a significant difference in DFS according to the DRS in our study subjects (P , 0.001) [ Fig. 1(B) ]. The 5-year DFS rates were 97% in the excellent response group, 86% in the indeterminate group, 60% in the biochemical incomplete response group, and 6% in the structural incomplete group. The risk of recurrent/persistent disease was significantly higher in the indeterminate group (HR, 10.20; 95% CI, 1.02 to 98.8; P = 0.045) and in the structural incomplete group (HR, 98.68; 95% CI, 12.97 to 750.9; P , 0.001) compared with the excellent response group (Table 5) .
Association between ATA pediatric risk classification and DRS When we evaluated the association between ATA pediatric risk classification and DRS based on the response to the initial therapy, 82% of the low-risk patients, 62% of the intermediate-risk patients, and 4% of the high-risk patients were in the excellent-response group during the follow up (Table 6 ). About 12% of the low-risk patients, 19% of the intermediate-risk patients, and 65% of the high-risk patients were classified as structural incomplete response during the follow up. In addition, 5% of the intermediate-risk patients and 13% of the high-risk patients were in the biochemical incomplete response group. In total, 12% of the low-risk patients, 24% of the intermediate-risk patients, and 78% of the high-risk patients had biochemical or structural disease progression after initial therapy.
Discussion
In this study, we evaluated the usefulness of initial ATA risk classification and DRS based on the response to the initial therapy when predicting recurrent or persistent disease in pediatric patients with DTC. We have presented a practical application of initial risk classification based on ATA risk groups by using the number and size of metastatic cervical LNs. The risk of recurrent/persistent disease was significantly higher in the ATA high-risk group but was not evident in the indeterminate-risk group compared with the low-risk group. Our results suggest that DRS could be useful for the prediction of recurrent/persistent DTC in pediatric patients. Patients in the intermediate-risk and structural incomplete groups had a significantly higher risk of recurrent/persistent disease compared with the excellent-response group. In our study, only 22% of patients were classified as low risk by initial ATA risk classification. However, 49% of patients were classified as "excellent response" during the follow up. About 62% of the indeterminate group and 4% of the high-risk group were reclassified as excellent response by DRS. Excellent response in DRS could predict NED in most patients; only 1 of 38 patients in the excellent response group had structural persistent/recurrent disease. Applying DRS could be more useful for patients NED (n = 46) 95% (16) 68% (25) 22% (5) 97% (37) 60% (6) 40% (2) 4% ( (1) 8% (2) Structural, persistent/ recurrent disease (n = 27) 6% (1) 24% (9) 74% (17) 3% (1) 30% (3) 40% (2) 88% ( press.endocrine.org/journal/jcemwho were initially classified as intermediate ATA risk because 24% of them were reclassified as biochemical or structural incomplete response, whereas 62% of them were reclassified as excellent response. Clinical implications of DRS could provide more information to adjust the intensity of follow-up and management strategy for pediatric patients with DTC. Recent management guidelines for pediatric patients with DTC recommended the initial ATA risk classification, but these definitions were not practical to use in clinics. In the present study, we specifically defined incidental N1a disease as clinical N0 disease with #5 N1 micrometastases according to the recent ATA guidelines for adult patients with DTC (19) . We also specifically defined extensive N1b disease as .10 metastatic LNs in the lateral neck or pathologic N1b disease with any metastatic LN $3 cm according to the recent ATA guidelines for adult patients with DTC and our previous study (19, 23) . Our previous study reported that patients with .10 metastatic LNs in the lateral neck had a 1.7 times higher risk of persistent or recurrent disease than those with #10 metastatic LNs in the lateral neck (23) . Our present study defined the detailed criteria of ATA risk classification for pediatric patients with DTC. These findings might contribute to appropriate postoperative initial staging and postoperative management of pediatric patients with DTC. Further validation studies might be needed.
The extent of surgical treatment (i.e., lobectomy vs. total thyroidectomy) was important for the recurrent disease of pediatric patients with thyroid cancer. Newman et al. (9) reported that the extent of surgery does not affect disease prognosis because long-term survival rate was 90% in pediatric patients with DTC. However, several studies suggested that total thyroidectomy could decrease the risk of recurrence and subsequent additional surgical treatment (13, 27, 28) . Recent ATA guidelines also recommend total thyroidectomy because of frequent bilateral and multifocal disease in pediatric patients (16) . Total thyroidectomy also could optimize the use of RAI ablation and Tg as a tumor maker for patients with DTC. In our study, most patients (83%) underwent total thyroidectomy, and only 17% underwent unilateral thyroid surgery because of limited extent of disease. Postoperative complications were reported to be associated with the extent of surgery and were more frequent in younger patients (29, 30) . In our study, 23% of patients had postoperative complications, including transient hypoparathyroidism (9%), permanent hypoparathyroidism (5%), and transient hoarseness (5%). These rates of complications seems to be similar to a previous study in a high-volume tertiary hospital (31) .
This study had some limitations. It was a historical cohort study that included a relatively small number of patients and a relatively short follow-up period. Furthermore, there is the possibility of selection bias because all the patients were from a single tertiary referral center. However, patients in our cohort study were treated and followed using a uniform protocol. Further studies are required to validate our application of ATA risk stratification and DRS in pediatric patients with DTC.
In summary, the initial ATA risk stratification reflecting the extent of disease by tumor size, localized invasion, and the number and size of cervical LN metastases was useful for predicting for the risk of structural persistent or recurrent disease in pediatric patients with DTC. DRS based on the response to initial therapy could provide additional useful prognostic information for predicting persistent/recurrent disease to modify the management planning for long-term follow up. 
